#moderna
moderna
7,692 views
56 Discussing
Hot
Latest
·
--
🧬 $MRNAB RISES 6.42% — BIOTECH EXPOSURE IS ON THE MOVE!
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
🧬 $MRNAB RISES 6.42% — BIOTECH EXPOSURE IS ON THE MOVE!
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
Current Price: $217.67
24H Change: +6.42%
$MRNAB is showing a healthy daily gain in this market snapshot, bringing Moderna-linked tokenized stock exposure into focus.
• The current move is positive.
• Keep an eye on price stability after the rally.
• Remember that company news and wider stock-market conditions can affect performance.
Important: MRNAB is a bStock product, not a regular crypto token. Understand its structure, risks, and trading hours before taking a position.
#MRNAB #Moderna #bStocks #MarketTrends
1
45
·
--
$MRNAB IS MOVING UP — CAN BUYERS TURN A STEADY GAIN INTO A BIGGER MOVE?
Moderna bStocks ($MRNAB) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
$MRNAB IS MOVING UP — CAN BUYERS TURN A STEADY GAIN INTO A BIGGER MOVE?
Moderna bStocks ($MRNAB ) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
Moderna bStocks ($MRNAB ) has gained 4.98% over the past 24 hours. The move is more measured than some of the day's biggest gainers, giving traders a reason to watch for a structured continuation rather than chase sudden volatility.
The key is to see whether buyers can hold the entry area and push through the next price levels.
Trade Setup
• Current Price: $215.27
• Buy Zone: $211.00 – $214.00
• Entry Point: Enter only after a confirmed bounce
• TP1: $218.00
• TP2: $222.00
• TP3: $228.00
• Stop Loss: $206.50
The Next Decision
• A hold above $211 could support a move toward $218.
• A clean break above $218 may open the way toward $222.
• A drop below $206.50 invalidates the proposed setup.
$MRNAB is a tokenized stock product. Verify its relationship to the underlying Moderna share, market hours, liquidity, and product risks before trading. Do not confuse a daily gain with a guaranteed continuation.
#MRNAB #Moderna #TokenizedStocks #MarketWatch
80
·
--
Bullish
$MRNA is trading at $206.06, rising 5.18%. The biotech stock is gaining attention as investors monitor developments in vaccines, medical research, and the company's future growth opportunities. Further movement will depend on market sentiment and company-specific developments.
$MRNA
{future}(MRNAUSDT)
#Write2Earn! #MRNA #Moderna #BiotechStocks
$MRNA is trading at $206.06, rising 5.18%. The biotech stock is gaining attention as investors monitor developments in vaccines, medical research, and the company's future growth opportunities. Further movement will depend on market sentiment and company-specific developments.
$MRNA
#Write2Earn! #MRNA #Moderna #BiotechStocks
$MRNA
#Write2Earn! #MRNA #Moderna #BiotechStocks
1
389
·
--
Good data, but the stock plunged 26% first: Moderna’s cancer vaccine gets doctors’ approval, but the market isn’t buying it
Last Thursday, late-stage data were released for Moderna and Merck’s personalized melanoma vaccine: among more than 1,100 patients, the risk of recurrence or death fell 42%, and the risk of distant metastasis fell 38%.
Analysts called the data “solid,” but the stock plunged as much as 26% intraday, its biggest one-day drop ever, briefly wiping out about $24 billion in market value.
It fell another 1.25% on Friday to $200.10, then dropped 7.3% in premarket trading Monday to $185.45, before clawing back to around $198 during the session.
The problem isn’t the data—it’s expectations: the stock is up 570% so far this year, and the market wanted the 49% from the previous small trial, not 42%.
Even more sobering is the valuation: Wall Street price targets are generally between $104 and $138. Goldman Sachs just raised its target to $137, while Redburn went straight to a Sell rating with an $81 target.
I think this is a classic “sell the news” situation: the data aren’t bad, but the 570% rally has already priced in the good news. In the short term, it’s a bubble deflation situation. Watch, don’t chase; the thesis is invalidated if it closes above $209.59 on the daily chart.
Do you think this is “good data unfairly punished,” or “it was up too much, so it deserved to fall”?
$MRNA $MRK $GS
#Moderna #U.S. stocks
The above does not constitute investment advice. DYOR; trading involves risk.
Good data, but the stock plunged 26% first: Moderna’s cancer vaccine gets doctors’ approval, but the market isn’t buying it
Last Thursday, late-stage data were released for Moderna and Merck’s personalized melanoma vaccine: among more than 1,100 patients, the risk of recurrence or death fell 42%, and the risk of distant metastasis fell 38%.
Analysts called the data “solid,” but the stock plunged as much as 26% intraday, its biggest one-day drop ever, briefly wiping out about $24 billion in market value.
It fell another 1.25% on Friday to $200.10, then dropped 7.3% in premarket trading Monday to $185.45, before clawing back to around $198 during the session.
The problem isn’t the data—it’s expectations: the stock is up 570% so far this year, and the market wanted the 49% from the previous small trial, not 42%.
Even more sobering is the valuation: Wall Street price targets are generally between $104 and $138. Goldman Sachs just raised its target to $137, while Redburn went straight to a Sell rating with an $81 target.
I think this is a classic “sell the news” situation: the data aren’t bad, but the 570% rally has already priced in the good news. In the short term, it’s a bubble deflation situation. Watch, don’t chase; the thesis is invalidated if it closes above $209.59 on the daily chart.
Do you think this is “good data unfairly punished,” or “it was up too much, so it deserved to fall”?
$MRNA $MRK $GS
#Moderna #U.S. stocks
The above does not constitute investment advice. DYOR; trading involves risk.
Last Thursday, late-stage data were released for Moderna and Merck’s personalized melanoma vaccine: among more than 1,100 patients, the risk of recurrence or death fell 42%, and the risk of distant metastasis fell 38%.
Analysts called the data “solid,” but the stock plunged as much as 26% intraday, its biggest one-day drop ever, briefly wiping out about $24 billion in market value.
It fell another 1.25% on Friday to $200.10, then dropped 7.3% in premarket trading Monday to $185.45, before clawing back to around $198 during the session.
The problem isn’t the data—it’s expectations: the stock is up 570% so far this year, and the market wanted the 49% from the previous small trial, not 42%.
Even more sobering is the valuation: Wall Street price targets are generally between $104 and $138. Goldman Sachs just raised its target to $137, while Redburn went straight to a Sell rating with an $81 target.
I think this is a classic “sell the news” situation: the data aren’t bad, but the 570% rally has already priced in the good news. In the short term, it’s a bubble deflation situation. Watch, don’t chase; the thesis is invalidated if it closes above $209.59 on the daily chart.
Do you think this is “good data unfairly punished,” or “it was up too much, so it deserved to fall”?
$MRNA $MRK $GS
#Moderna #U.S. stocks
The above does not constitute investment advice. DYOR; trading involves risk.
291
·
--
【U.S. Premarket Movers - Moderna $MRNAB 】
The cancer vaccine succeeded in Phase 3, yet Moderna $MRNA fell by a quarter in two days. It was at $184.47 premarket, down 7.81%, a 25% pullback from its October 21 high of $245.81.
The first point of comparison is the earlier data. The Phase 3 trial showed a 42% reduction in the risk of recurrence or death, versus 49% in Phase 2; distant metastases fell by 38%, versus 59% in Phase 2. That’s a 14% and 36% difference in relative risk reduction, respectively. The results are positive, but weaker than the version reported two years ago.
The real sticking point is overall survival. The HR was 0.77, with a confidence interval of 0.45 to 1.31. Since it crosses 1, the result doesn’t prove a benefit. The discontinuation rate was 14.0%, compared with 8.7% for Keytruda alone—1.6 times higher. Efficacy improved, but more people dropped out.
So analysts haven’t dismissed the efficacy. RBC said the results were clinically meaningful and the vaccine was likely to be approved; UBS said it was more confident about its potential in kidney and bladder cancers.
What they’ve lowered is their valuation: Brookline cut its 2030 EPS estimate from 19.11 to 18.19, while Redburn downgraded the stock straight to Sell. The stock rose from 29.49 to just over 200 this year, and a large part of its market cap reflects expectations for mRNA cancer treatments. The next catalyst is the non-small cell lung cancer data at ESMO: strong results, and this sell-off was an overreaction; mixed results, and a 25% drop may just be the beginning.
{spot}(MRNABUSDT)
#生物科技 #moderna #币安神算子
【U.S. Premarket Movers - Moderna $MRNAB 】
The cancer vaccine succeeded in Phase 3, yet Moderna $MRNA fell by a quarter in two days. It was at $184.47 premarket, down 7.81%, a 25% pullback from its October 21 high of $245.81.
The first point of comparison is the earlier data. The Phase 3 trial showed a 42% reduction in the risk of recurrence or death, versus 49% in Phase 2; distant metastases fell by 38%, versus 59% in Phase 2. That’s a 14% and 36% difference in relative risk reduction, respectively. The results are positive, but weaker than the version reported two years ago.
The real sticking point is overall survival. The HR was 0.77, with a confidence interval of 0.45 to 1.31. Since it crosses 1, the result doesn’t prove a benefit. The discontinuation rate was 14.0%, compared with 8.7% for Keytruda alone—1.6 times higher. Efficacy improved, but more people dropped out.
So analysts haven’t dismissed the efficacy. RBC said the results were clinically meaningful and the vaccine was likely to be approved; UBS said it was more confident about its potential in kidney and bladder cancers.
What they’ve lowered is their valuation: Brookline cut its 2030 EPS estimate from 19.11 to 18.19, while Redburn downgraded the stock straight to Sell. The stock rose from 29.49 to just over 200 this year, and a large part of its market cap reflects expectations for mRNA cancer treatments. The next catalyst is the non-small cell lung cancer data at ESMO: strong results, and this sell-off was an overreaction; mixed results, and a 25% drop may just be the beginning.
#生物科技 #moderna #币安神算子
The cancer vaccine succeeded in Phase 3, yet Moderna $MRNA fell by a quarter in two days. It was at $184.47 premarket, down 7.81%, a 25% pullback from its October 21 high of $245.81.
The first point of comparison is the earlier data. The Phase 3 trial showed a 42% reduction in the risk of recurrence or death, versus 49% in Phase 2; distant metastases fell by 38%, versus 59% in Phase 2. That’s a 14% and 36% difference in relative risk reduction, respectively. The results are positive, but weaker than the version reported two years ago.
The real sticking point is overall survival. The HR was 0.77, with a confidence interval of 0.45 to 1.31. Since it crosses 1, the result doesn’t prove a benefit. The discontinuation rate was 14.0%, compared with 8.7% for Keytruda alone—1.6 times higher. Efficacy improved, but more people dropped out.
So analysts haven’t dismissed the efficacy. RBC said the results were clinically meaningful and the vaccine was likely to be approved; UBS said it was more confident about its potential in kidney and bladder cancers.
What they’ve lowered is their valuation: Brookline cut its 2030 EPS estimate from 19.11 to 18.19, while Redburn downgraded the stock straight to Sell. The stock rose from 29.49 to just over 200 this year, and a large part of its market cap reflects expectations for mRNA cancer treatments. The next catalyst is the non-small cell lung cancer data at ESMO: strong results, and this sell-off was an overreaction; mixed results, and a 25% drop may just be the beginning.
#生物科技 #moderna #币安神算子
317
·
--
Bearish
🚨 $MRNAB DROPS 19.21% IN 24 HOURS! 📉
{spot}(MRNABUSDT)
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
🚨 $MRNAB DROPS 19.21% IN 24 HOURS! 📉
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
💰 Price: $194.41
🔴 MRNAB faces heavy selling pressure after falling sharply from recent highs. Can buyers defend $190, or will the decline continue?
📊 BOUNCE BACK OR MORE DOWNSIDE? 👀
💬 BULLISH 🟢 or BEARISH 🔴? Share your prediction!
⚠️ High volatility — manage your risk.
#MRNAB #Moderna #Crypto #Trading
97
·
--
Moderna closed at $242, while Wall Street’s average price target is just $101—the stock is trading at 2.4 times that target. I’m not chasing it before Saturday’s data.
Here’s what happened: Moderna rose 6.7% on Tuesday, hitting a 52-week high of $243.98 intraday.
A year ago, its lowest closing price was just $22.36. It’s now up more than 10-fold; when preliminary Phase 3 results came out on August 19, the stock jumped 177% in a single day.
Full Phase 3 data for the personalized melanoma vaccine developed with Merck will be presented at ESMO on October 24 at 22:30 Beijing time.
I think most of the good news is already priced in. Unless the data are truly impressive, the stock could easily suffer a “sell the news” reaction. Company insiders have also sold about $33.9 million worth of shares over the past 90 days.
What I’m doing: neither chasing the stock nor shorting it ahead of the data.
I’ll take another look if it holds above $243.98 after the data. A break below the October 16 low of $208.92 would mean expectations have played out.
Will you hold Moderna over the weekend ahead of Saturday evening’s data—yes or no?
$MRNA $MRK
#Moderna #癌症疫苗
Moderna closed at $242, while Wall Street’s average price target is just $101—the stock is trading at 2.4 times that target. I’m not chasing it before Saturday’s data.
Here’s what happened: Moderna rose 6.7% on Tuesday, hitting a 52-week high of $243.98 intraday.
A year ago, its lowest closing price was just $22.36. It’s now up more than 10-fold; when preliminary Phase 3 results came out on August 19, the stock jumped 177% in a single day.
Full Phase 3 data for the personalized melanoma vaccine developed with Merck will be presented at ESMO on October 24 at 22:30 Beijing time.
I think most of the good news is already priced in. Unless the data are truly impressive, the stock could easily suffer a “sell the news” reaction. Company insiders have also sold about $33.9 million worth of shares over the past 90 days.
What I’m doing: neither chasing the stock nor shorting it ahead of the data.
I’ll take another look if it holds above $243.98 after the data. A break below the October 16 low of $208.92 would mean expectations have played out.
Will you hold Moderna over the weekend ahead of Saturday evening’s data—yes or no?
$MRNA $MRK
#Moderna #癌症疫苗
Here’s what happened: Moderna rose 6.7% on Tuesday, hitting a 52-week high of $243.98 intraday.
A year ago, its lowest closing price was just $22.36. It’s now up more than 10-fold; when preliminary Phase 3 results came out on August 19, the stock jumped 177% in a single day.
Full Phase 3 data for the personalized melanoma vaccine developed with Merck will be presented at ESMO on October 24 at 22:30 Beijing time.
I think most of the good news is already priced in. Unless the data are truly impressive, the stock could easily suffer a “sell the news” reaction. Company insiders have also sold about $33.9 million worth of shares over the past 90 days.
What I’m doing: neither chasing the stock nor shorting it ahead of the data.
I’ll take another look if it holds above $243.98 after the data. A break below the October 16 low of $208.92 would mean expectations have played out.
Will you hold Moderna over the weekend ahead of Saturday evening’s data—yes or no?
$MRNA $MRK
#Moderna #癌症疫苗
423
·
--
Bullish
🚨 Moderna company "Moderna" will be listed on the "Nasdaq 100" after its stock surged massively, exceeding 600% in 2026.
This strong rise has pushed "Moderna" to become one of the most prominent companies listed in the index, representing a radical shift in the company’s trajectory this year.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
{spot}(MRNABUSDT)
🚨 Moderna company "Moderna" will be listed on the "Nasdaq 100" after its stock surged massively, exceeding 600% in 2026.
This strong rise has pushed "Moderna" to become one of the most prominent companies listed in the index, representing a radical shift in the company’s trajectory this year.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
This strong rise has pushed "Moderna" to become one of the most prominent companies listed in the index, representing a radical shift in the company’s trajectory this year.
#stocks #BStocks #الأسهم_الأمريكية #moderna
$MRNAB
1
39
·
--
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
#ModernaRisesOver12%
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
Moderna (MRNA) shares shot up more than 12% yesterday, closing at about $67.
Why the big jump?
> The company shared exciting updates on new mRNA treatments for cancer prevention, autoimmune diseases and more.
> Good news from the FDA on their flu vaccine also helped boost confidence.
This is a big win for the biotech company, which has been working hard to expand beyond COVID vaccines. Investors are feeling optimistic about the future!
What do you think — is this the start of something bigger for Moderna?
#Moderna #Stocks #MRNA
MRNAonAlpha
MRNAUS-0.52%
93
·
--
Bullish
$MRNAB is stabilizing near support levels after a notable pull-back, showing signs of buyer defense around current prices. A successful consolidation here could ignite a relief bounce to challenge upper supply levels.
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
{future}(TUTUSDT)
$ZEC
{future}(ZECUSDT)
{spot}(MRNABUSDT)
$MRNAB is stabilizing near support levels after a notable pull-back, showing signs of buyer defense around current prices. A successful consolidation here could ignite a relief bounce to challenge upper supply levels.
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
$ZEC
Target 1: 148.00 Target 2: 152.00 Target 3: 156.00
#MRNAB #Moderna #Crypto
$TUT
$ZEC
3
380
·
--
$MRNAon has displayed a powerful initial breakout, pumping over 12% to test a high near 159.42 before encountering quick resistance. Price has since retraced on the 15m chart and is currently forming a tight, low-volatility consolidation range right around the 145.66 level. A successful defense of this base near 142.40 will be crucial for buyers to build momentum for another leg upward.
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
{future}(TRUMPUSDT)
{alpha}(560x01486675da0764ee780ea7cb65c33062e9b2d28c)
$ZEC
{future}(ZECUSDT)
$MRNAon has displayed a powerful initial breakout, pumping over 12% to test a high near 159.42 before encountering quick resistance. Price has since retraced on the 15m chart and is currently forming a tight, low-volatility consolidation range right around the 145.66 level. A successful defense of this base near 142.40 will be crucial for buyers to build momentum for another leg upward.
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
$ZEC
Target 1: 151.00 Target 2: 159.40 Target 3: 168.00
#MRNAon #Moderna #CryptoTrading #Altcoins
$TRUMP
$ZEC
1
239
·
--
This is an amazing development. Shares of "Moderna" rose by about 150% today, jumping to second place among the best-performing stocks in the "S&P 500" index for 2026. Now, the stock is alone at the top of this distinguished spot on a list dominated by artificial intelligence companies, with only the stock of "Sandisk" ahead of it.
{stock_us}(MRNA.US)
#stocks #moderna #SNDK #S&P500
{stock_us}(DELL.US)
This is an amazing development. Shares of "Moderna" rose by about 150% today, jumping to second place among the best-performing stocks in the "S&P 500" index for 2026. Now, the stock is alone at the top of this distinguished spot on a list dominated by artificial intelligence companies, with only the stock of "Sandisk" ahead of it.
#stocks #moderna #SNDK #S&P500
#stocks #moderna #SNDK #S&P500
1
105
·
--
Bullish
🚨 MODERNA SURGES 14% AFTER CANCER-THERAPY BREAKTHROUGH 📈
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
{future}(MRNAUSDT)
#moderna #MRNAon
🚨 MODERNA SURGES 14% AFTER CANCER-THERAPY BREAKTHROUGH 📈
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
#moderna #MRNAon
Moderna jumped 14.36% after Moderna and Merck reported positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in high-risk melanoma.
🏦 Major banks responded by raising Moderna’s price targets, with Bank of America moving from $40 to $170 and Piper Sandler from $77 to $167.
🎯 TRADING VIEW: BUY 📈
The strong clinical results and major target upgrades create a bullish catalyst, but traders should monitor whether momentum holds after the sharp rally.
❓ Can Moderna extend this breakout? "CLICK ON THE BELOW YELLOW COIN TAG TO GO TO DESIRED TRADING PAGE TO GET BENEFIT TRADE"$MRNA
#moderna #MRNAon
1
363
·
--
Bullish
Verified
BIO-5.53%
MRNAUS-0.52%
704
·
--
Bullish
Just 7 hours ago, I brought you a great news that will boost the stock of company $MRNA.US . Back then, the price was $120, and I told you it would rise as shown below 👇 Now the stock price has reached $194 🔥👌🚀🚀
#stocks #MRNA #moderna #Stocks_DAB3
{stock_us}(MRNA.US)
Just 7 hours ago, I brought you a great news that will boost the stock of company $MRNA.US . Back then, the price was $120, and I told you it would rise as shown below 👇 Now the stock price has reached $194 🔥👌🚀🚀
#stocks #MRNA #moderna #Stocks_DAB3
#stocks #MRNA #moderna #Stocks_DAB3
DAB3_1997
·
--
Bullish$MRNA.US share rises strongly thanks to the successful results of a vaccine against melanoma cancer. 💉
#stocks #stoksDAB3 #MRNA
#stocks #stoksDAB3 #MRNA
MRNAUS-0.52%
1
31
·
--
Bullish
Jumped shares of "Moderna" (MRNA) by 150% - achieving the best daily performance in its history - after showing that a cancer vaccine has the potential to prevent recurrence of melanoma. 📈 📈
{stock_us}(MRNA.US)
#stocks #stocksDAB3 #stockDAB3 #moderna
Jumped shares of "Moderna" (MRNA) by 150% - achieving the best daily performance in its history - after showing that a cancer vaccine has the potential to prevent recurrence of melanoma. 📈 📈
#stocks #stocksDAB3 #stockDAB3 #moderna
#stocks #stocksDAB3 #stockDAB3 #moderna
MRNAUS-0.52%
1
43
·
--
Verified
🚨 Our manager and Merck announce major progress in a personalized cancer vaccine using mRNA technology
In a notable development in the field of cancer treatment, Moderna and Merck have announced positive results from their Phase 3 trial of a personalized cancer vaccine based on mRNA technology.
The concept is different from traditional vaccines:
The vaccine is designed specifically for each patient based on the genetic mutations found within the tumor, with the aim of helping the immune system recognize and attack cancer cells with greater precision.
According to the announcement, the study included 1,137 patients with high-risk skin cancer. The vaccine was used together with Merck’s Keytruda after the tumor was surgically removed.
📌 The reported results showed:
• A significant reduction in the risk of cancer recurrence
• A lower chance of the disease spreading to other parts of the body
Moderna hopes to move forward toward bringing the treatment to market after completing the necessary regulatory procedures.
📈 The news strongly impacted the companies’ shares:
Merck reached new record levels, while Moderna’s stock jumped sharply, with gains of more than 180% during the recent upward surge, trading above $181 in after-hours trading according to the figures shared in connection with the news.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
🚨 Our manager and Merck announce major progress in a personalized cancer vaccine using mRNA technology
In a notable development in the field of cancer treatment, Moderna and Merck have announced positive results from their Phase 3 trial of a personalized cancer vaccine based on mRNA technology.
The concept is different from traditional vaccines:
The vaccine is designed specifically for each patient based on the genetic mutations found within the tumor, with the aim of helping the immune system recognize and attack cancer cells with greater precision.
According to the announcement, the study included 1,137 patients with high-risk skin cancer. The vaccine was used together with Merck’s Keytruda after the tumor was surgically removed.
📌 The reported results showed:
• A significant reduction in the risk of cancer recurrence
• A lower chance of the disease spreading to other parts of the body
Moderna hopes to move forward toward bringing the treatment to market after completing the necessary regulatory procedures.
📈 The news strongly impacted the companies’ shares:
Merck reached new record levels, while Moderna’s stock jumped sharply, with gains of more than 180% during the recent upward surge, trading above $181 in after-hours trading according to the figures shared in connection with the news.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
In a notable development in the field of cancer treatment, Moderna and Merck have announced positive results from their Phase 3 trial of a personalized cancer vaccine based on mRNA technology.
The concept is different from traditional vaccines:
The vaccine is designed specifically for each patient based on the genetic mutations found within the tumor, with the aim of helping the immune system recognize and attack cancer cells with greater precision.
According to the announcement, the study included 1,137 patients with high-risk skin cancer. The vaccine was used together with Merck’s Keytruda after the tumor was surgically removed.
📌 The reported results showed:
• A significant reduction in the risk of cancer recurrence
• A lower chance of the disease spreading to other parts of the body
Moderna hopes to move forward toward bringing the treatment to market after completing the necessary regulatory procedures.
📈 The news strongly impacted the companies’ shares:
Merck reached new record levels, while Moderna’s stock jumped sharply, with gains of more than 180% during the recent upward surge, trading above $181 in after-hours trading according to the figures shared in connection with the news.
#Moderna #Merck #MRNA #Cancer #Keytruda #Stocks #Biotech
1
590
#ModernaRisesOver12%
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
{spot}(SPCXBUSDT)
$MRNAon
{alpha}(560x01486675da0764ee780ea7cb65c33062e9b2d28c)
#ModernaRisesOver12%
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
🚨 Wall Street Wasn't Watching... Until Modern$MRNAon Exploded +12%!
In a market where most investors were focused on AI and crypto, Moderna suddenly stole the spotlight with a double-digit rally.
Why are institutional investors suddenly paying attention again?
Is this the start of a biotech comeback... or are traders chasing a short-term headline?
One thing is clear: when a mega-cap biotech moves this fast, the entire healthcare sector starts getting watched.
👇 What's your prediction?
🟢 Rally continues
🔴 Profit-taking starts
🟡 Too early to tell
#ModernaRisesOver12 #Moderna #Stocks
$SPCXB
$MRNAon
1
134
·
--
Article
STOCKS | Moderna Surges 50% Premarket, Merck Gains 5.6%Moderna (MRNA.O) experienced a remarkable surge of 50% in premarket trading, according to Jin10, reflecting investor optimism and strong market confidence. The biotech company’s shares jumped significantly ahead of the regular trading session, signaling a major rally driven by positive developments or market sentiment.
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
STOCKS | Moderna Surges 50% Premarket, Merck Gains 5.6%
Moderna (MRNA.O) experienced a remarkable surge of 50% in premarket trading, according to Jin10, reflecting investor optimism and strong market confidence. The biotech company’s shares jumped significantly ahead of the regular trading session, signaling a major rally driven by positive developments or market sentiment.
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
Meanwhile, Merck (MRK.N) also saw a notable increase, gaining 5.6% in premarket, suggesting broader strength in the healthcare sector. The gains for Merck, although more moderate compared to Moderna, indicate a favorable outlook for pharmaceutical giants amid ongoing industry developments or recent news catalysts.
The sharp rise in Moderna’s stock price is noteworthy, as such a substantial move in premarket activity often indicates investor anticipation of upcoming earnings reports, positive clinical trial results, or strategic corporate announcements. The market reaction underscores the high level of interest and speculation surrounding biotech stocks in the current trading environment.
These movements in Moderna and Merck stocks are being closely watched by traders and investors, as they could influence broader market dynamics and sector sentiment. The biotech sector remains volatile and sensitive to news, making these premarket surges significant signals for the day’s trading activity. #Moderna #Merck #BiotechStocks
1
160
·
--
Verified
🚨 THIS IS WHY $MRNA.US IS EXPLODING! 📈
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
🚨 THIS IS WHY $MRNA.US IS EXPLODING! 📈
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
Moderna just dropped positive Phase 3 results for its personalized mRNA cancer therapy with Merck’s KEYTRUDA.
The trial showed significant improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in melanoma patients.
And the market reacted HARD:
$MRNA: +140% 🚀🔥
Personalized mRNA cancer vaccines just took a massive step forward. 🧬💉
#MRNA #moderna #CancerCure #StocksTalks
MRNAUS-0.52%
373
Log in to explore more content
Join global crypto users on Binance Square
⚡️ Get latest and useful information about crypto.
💬 Trusted by the world’s largest crypto exchange.
👍 Discover real insights from verified creators.
Email / Phone number
Trending Topics
1
#UniswapA16zSeekDeFiExemptionFromIllinoisCryptoTax
22,332 views
711 Discussing
2
#HKDollarStablecoinHKDAPToLaunchOnSolana
15,978 views
448 Discussing
3
#$1.5BInLeveragedCryptoBetsLiquidated
35,290 views
240 Discussing
4
#TrezorSaysCryptoBilisSoldWalletMayContainMaliciousComponents
2,483 views
64 Discussing
5
#KOSPIFalls3.53%BackBelow6000
60,479 views
1,070 Discussing
6
#AmazonSharesFallAbout7%InPremarketTrading
27,314 views
573 Discussing
7
#USMidtermElections
236,649 views
2,331 Discussing
8
#StrategySTRCReaches$99.95ForFirstTimeIn165Days
23,199 views
93 Discussing
9
#BinanceWillListPredictPREDICT
90,029 views
1,373 Discussing
10
#SwitzerlandFirstSpotBitcoinETFExpectedToTradeInNovember
3,049 views
107 Discussing